BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 2471275)

  • 1. Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
    Morstyn G; Lieschke GJ; Sheridan W; Layton J; Cebon J; Fox RM
    Semin Hematol; 1989 Apr; 26(2 Suppl 2):9-13. PubMed ID: 2471275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematologic effects of recombinant murine granulocyte-macrophage colony-stimulating factor on the peripheral blood and bone marrow.
    Ulich TR; del Castillo J; McNiece I; Watson L; Yin SM; Andresen J
    Am J Pathol; 1990 Aug; 137(2):369-76. PubMed ID: 1696784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The promise of colony-stimulating factors in clinical practice.
    Glaspy JA; Ambersley JM
    Oncol Nurs Forum; 1990; 17(1 Suppl):20-4. PubMed ID: 1689043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects.
    Thompson JA; Lee DJ; Kidd P; Rubin E; Kaufmann J; Bonnem EM; Fefer A
    J Clin Oncol; 1989 May; 7(5):629-37. PubMed ID: 2651578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical applications of the myeloid growth factors.
    Glaspy JA; Golde DW
    Semin Hematol; 1989 Apr; 26(2 Suppl 2):14-7. PubMed ID: 2471274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy.
    Lieschke GJ; Maher D; Cebon J; O'Connor M; Green M; Sheridan W; Boyd A; Rallings M; Bonnem E; Metcalf D
    Ann Intern Med; 1989 Mar; 110(5):357-64. PubMed ID: 2644886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.
    Welte K; Zeidler C; Reiter A; Müller W; Odenwald E; Souza L; Riehm H
    Blood; 1990 Mar; 75(5):1056-63. PubMed ID: 1689595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor.
    Steward WP; Scarffe JH; Bonnem E; Crowther D
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():335-46. PubMed ID: 2182743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth factor-assisted chemotherapy--the Manchester experience.
    Crowther D; Scarffe JH; Howell A; Thatcher N; Bronchud M; Steward WP; Testa N; Dexter M
    Ciba Found Symp; 1990; 148():201-10; discussion 211-4. PubMed ID: 1690624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
    Haematol Blood Transfus; 1990; 33():717-23. PubMed ID: 2182461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic growth factors: biology and clinical application.
    Gabrilove JL; Jakubowski A
    J Natl Cancer Inst Monogr; 1990; (10):73-7. PubMed ID: 1693284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
    Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of therapy with recombinant granulocyte-macrophage colony-stimulating factor administered by IV bolus or continuous infusion.
    Rifkin RM; Hersh EM; Salmon SE
    Behring Inst Mitt; 1988 Aug; (83):125-33. PubMed ID: 3071327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study.
    Steward WP; Scarffe JH; Austin R; Bonnem E; Thatcher N; Morgenstern G; Crowther D
    Br J Cancer; 1989 Jan; 59(1):142-5. PubMed ID: 2667607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor.
    Vadhan-Raj S; Velasquez WS; Butler JJ; LeMaistre A; Lepe-Zuniga J; Keating MJ; Koller CA; Gutterman JU
    Am J Hematol; 1990 Mar; 33(3):189-97. PubMed ID: 2405649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous recombinant granulocyte-macrophage colony-stimulating factor used as a single agent and in an alternating regimen with azidothymidine in leukopenic patients with severe human immunodeficiency virus infection.
    Pluda JM; Yarchoan R; Smith PD; McAtee N; Shay LE; Oette D; Maha M; Wahl SM; Myers CE; Broder S
    Blood; 1990 Aug; 76(3):463-72. PubMed ID: 2198957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical use of hematopoietic growth factors.
    Appelbaum FR
    Semin Hematol; 1989 Jul; 26(3 Suppl 3):7-14. PubMed ID: 2477905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.